1. Home
  2. PIII vs COEP Comparison

PIII vs COEP Comparison

Compare PIII & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIII
  • COEP
  • Stock Information
  • Founded
  • PIII 2015
  • COEP 2017
  • Country
  • PIII United States
  • COEP United States
  • Employees
  • PIII N/A
  • COEP N/A
  • Industry
  • PIII Medical/Nursing Services
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PIII Health Care
  • COEP Health Care
  • Exchange
  • PIII Nasdaq
  • COEP Nasdaq
  • Market Cap
  • PIII 37.5M
  • COEP 32.4M
  • IPO Year
  • PIII N/A
  • COEP N/A
  • Fundamental
  • Price
  • PIII $0.23
  • COEP $13.17
  • Analyst Decision
  • PIII Buy
  • COEP
  • Analyst Count
  • PIII 3
  • COEP 0
  • Target Price
  • PIII $2.38
  • COEP N/A
  • AVG Volume (30 Days)
  • PIII 1.2M
  • COEP 111.7K
  • Earning Date
  • PIII 03-27-2025
  • COEP 03-25-2025
  • Dividend Yield
  • PIII N/A
  • COEP N/A
  • EPS Growth
  • PIII N/A
  • COEP N/A
  • EPS
  • PIII N/A
  • COEP N/A
  • Revenue
  • PIII $1,476,630,000.00
  • COEP N/A
  • Revenue This Year
  • PIII $21.45
  • COEP N/A
  • Revenue Next Year
  • PIII N/A
  • COEP N/A
  • P/E Ratio
  • PIII N/A
  • COEP N/A
  • Revenue Growth
  • PIII 25.38
  • COEP N/A
  • 52 Week Low
  • PIII $0.17
  • COEP $2.31
  • 52 Week High
  • PIII $1.20
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • PIII 60.65
  • COEP 66.28
  • Support Level
  • PIII $0.19
  • COEP $8.65
  • Resistance Level
  • PIII $0.25
  • COEP $12.95
  • Average True Range (ATR)
  • PIII 0.02
  • COEP 1.60
  • MACD
  • PIII 0.01
  • COEP -0.11
  • Stochastic Oscillator
  • PIII 77.31
  • COEP 89.50

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: